Modern cold calling for B2B SaaS founders for healthcare and life sciences
A founder-first breakdown of modern cold calling — the parts you have to own personally, the parts you can delegate, and the traps that eat the first 18 months. Written for commercial leaders at healthtech, medtech, and life-sciences companies.
This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install modern cold calling has to reflect that reality from day one.
If you are a B2B SaaS founder still under $5m ARR, modern cold calling is not something you delegate on day one. It is using the phone as a precision tool, not a volume weapon, and until it works you cannot describe your business without hand-waving.
The founder value in modern cold calling is that one connect on the phone beats 40 emails on the right day. You bring context no hire can replicate — the reason you started the company, the exact objection you heard on call number seven, the phrase a customer used that finally clicked.
Own the strategy, the first 30 live cycles, and the weekly review. Delegate the tooling, the list building, and the reporting. Founders who invert that order end up hiring around a broken model.
The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Modern cold calling is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.
Instrument connects per hour on ICP dials from day one — even if the number is embarrassing. You cannot debug what you do not measure, and every board meeting after Series A will start with this chart.
The founder trap in modern cold calling is power dialers that torch the list in a week. It always looks reasonable at the time. Write the trap on a sticky note and stick it on your monitor.
The moment to hand off modern cold calling is when you can predict the number two weeks out and defend the assumptions behind it. Not before. VP hires that arrive earlier tend to leave inside 14 months.
Founders who take modern cold calling seriously in year one write category-defining companies in year three. The compounding is that stark.
Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing modern cold calling properly rather than half-heartedly across three vendors.
Frequently asked questions
Sales · healthcare — answered
- Does modern cold calling work for healthcare and life sciences?
- Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
- Should the founder personally run modern cold calling?
- Yes, until you can predict the number two weeks out. Then hand off the ops and keep the strategy.
- When can I hire someone to own modern cold calling?
- When the metric is legible, the operating rhythm is documented, and you would rather work on the next constraint.
- What is the founder-specific mistake with modern cold calling?
- Power dialers that torch the list in a week — usually because the founder wants to move on before the model is proven.
- How much of my week should modern cold calling take as a founder?
- Roughly a third for the first two quarters, dropping to a weekly review once the metric is stable.
- What is the healthcare specific pitfall with modern cold calling?
- Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.
Growth Broker editorial
Filed under sales · healthcare